期刊
RHEUMATOLOGY
卷 50, 期 12, 页码 2233-2236出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/ker273
关键词
Fibromyalgia; Fragile X-associated tremor ataxia syndrome; Fragile X mental retardation 1 gene; Genetic counselling
类别
资金
- NICHD [HD02274, HD055510]
- NIA [AG032119, UL1 RR024146]
- Administration for Developmental Disabilities [90DD05969]
- Novartis
- Roche
- Seaside Therapeutics
- Curemark
- Forest
- [RL1AG032115]
- [UL1 DE019583]
- [HD036071]
Methods. A sample of patients was selected that participated in studies at two tertiary referral academic centres on the phenotype and therapy of FXTAS. Results. This selected sample of patients, five female premutation carriers, has FM symptoms or diagnoses and other central sensitivity syndromes. Conclusion. Since FM affects 2-4% of the world's population and about 1 in 250 females are FMR1 carriers, a study screening females with FM for the presence of the FMR1 premutation is worthwhile. A finding of increased prevalence of FMR1 carriers among females with FM would impact the standard evaluation of FM. Presently, guidelines for FMR1 genetic testing includes early menopause, congenital intellectual disability, autism spectrum disorder, tremor or ataxia, and a family history of FXTAS or fragile X syndrome. The latter is a common cause of autism and developmental delay. Such testing is important because female carriers are at risk of having a child with fragile X syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据